- Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume.
- Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% … [+37810 chars]
LazyNews Desk
Finance
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress - Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Login
Sign in to comment with your preferred method.
Or register with email